GE Healthcare says its Serena Bright is now available in the United States following U.S. FDA 510(k) clearance. Serena Bright is the industry\u2019s first contrast-enhanced guided biopsy solution allowing clinicians to conduct breast biopsy exams with contrast guidance using the same mammography equipment as that used for screening or diagnostic mammography.
\nTypically, for lesions found with contrastenhanced mammography and not seen on ultrasound, clinicians will use other imaging guidance, such as MRI, for biopsy procedures. Following an abnormal mammogram, it can take several weeks to get an MRI biopsy.
\nAs the backlog of cancer screenings caused by Covid-19 persists, delays in diagnosis will likely lead to presentation at more advanced stages and poorer clinical outcomes, with one study pointing to a potential increase of 33,890 excessive cancer deaths in the U.S. alone.
\nSerena Bright may help decrease these delays, allowing follow-up biopsy procedures to be done in a matter of days, rather than several weeks for MRI biopsy. When compared to MRI-biopsy guided therapy, the potential benefits of Contrast Enhanced Spectral Mammography (CESM) biopsy include shortened procedure time and improved overall patient experience.
\nKey to this technology\u2019s application is GE Healthcare\u2019s SenoBright HD CESM, a diagnostic breast exam with iodine-based contrast that provides high sensitivity for more accurate breast cancer diagnosis.
\nBy highlighting areas of unusual blood flow to localize lesions that need to be biopsied, CESM biopsy \u2013 Serena Bright \u2013 provides excellent image quality to help improve clinical confidence.
\nFor more information, visit: www.gehealthcare.com\/products\/ mammography\/serena-bright<\/link>\n<\/p>\n
Supplier:<\/strong> GE Healthcare
\nWebsite:<\/strong> http:\/\/www.gehealthcare.com\/products\/mammography\/serena-bright<\/a><\/p>\n